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According to the World Health Organization, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/
CFS) is a neurological disease characterized by widespread inflammation and multi-systemic neuropa-
thology. Aetiology and pathogenesis are unknown, and several agents have been proposed as causative
agents or as factors perpetuating the syndrome. Exposure to heavy metals, with particular reference to
mercury and gold in dental amalgams, has been considered among the triggers of ME/CFS. Here we
hypothesize that cadmium, a widespread occupational and environmental heavy metal pollutant, might
be associated with some of the neurological findings described in ME/CFS. In fact, ME/CFS patients show a
decrease of the volume of the gray matter in turn associated with objective reduction of physical activity.
Cadmium induces neuronal death in cortical neurons through a combined mechanism of apoptosis and
necrosis and it could then be hypothesized that cadmium-induced neuronal cell death is responsible
for some of the effects of cadmium on the central nervous system, i.e. a decrease in attention level and
memory in exposed humans as well as to a diminished ability for training and learning in rats, that
are symptoms typical of ME/CFS. This hypothesis can be tested by measuring cadmium exposure in a
cohort of ME/CFS patients compared with matched healthy controls, and by measuring gray matter vol-
ume in un-exposed healthy controls, exposed non-ME/CFS subjects, un-exposed ME/CFS patients and
exposed ME/CFS patients. In addition, we hypothesize that cadmium exposure could be associated with
reduced cerebral blood flow in ME/CFS patients because of the disruptive effects of cadmium on angio-
genesis. In fact, cadmium inhibits angiogenesis and low global cerebral flow is associated with abnormal
brain neuroimaging results and brain dysfunction in the form of reduced cognitive testing scores in ME/CFS
patients. This hypothesis can be tested by measuring cerebral cortex blood flow in un-exposed healthy
controls, exposed non-ME/CFS subjects, un-exposed ME/CFS patients and exposed ME/CFS patients. If
our hypothesis is demonstrated correct, the consequences could affect prevention, early diagnosis, and
treatment of ME/CFS. Implications in early diagnosis could entail the evaluation of symptoms typical
of ME/CFS in cadmium-exposed subjects as well as the search for signs of exposure to cadmium in sub-
jects diagnosed with ME/CFS. Nutritional supplementation of magnesium and zinc could then be consid-
ered, since these elements have been proposed in the prophylaxis and therapy of cadmium exposure, and
magnesium was demonstrated effective on ME/CFS patients’ symptom profiles.
 2012 Elsevier Ltd. All rights reserved.Introduction
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
is the term used to define a complex array of symptoms that in-
cludes, but is not limited to, profound, debilitating fatigue, lasting
for at least six months and resulting in a substantial reduction of
daily activities [1]. It is classified as a neurological disease in the
World Health Organization’s International Classification of Diseasesll rights reserved.
: +39 055 4379500.(ICDG93.3), and it is characterized bywidespread inflammation and
multi-systemic neuropathology [2]. Although according to the
recent International Consensus Criteria it is probably more appro-
priate to use only the term ‘‘Myalgic Encephalomyelitis’’ [2], in this
article we refer to the syndrome using the traditional double
acronymME/CFS. Under this definition, it is estimated that the syn-
drome affects millions people worldwide, and its prevalence is cal-
culated in between 400 and 2500 adults per 100,000 population [3].
Both aetiology and pathogenesis are unknown, and a number of
agents have been proposed either as causative agents or as factors
contributing to the perpetuation of the symptoms. As in many
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common clinical picture. Although a trigger cannot be necessarily
considered an etiological agent, according to a recent review, sev-
eral events may act as triggers, from external environmental or
infectious events, such as chemical exposure or infections, to psy-
chological and social factors that may be critical in maintaining the
chronic condition of the syndrome [4]. The hypothesis of a retrovi-
rus being associated with ME/CFS was postulated in 2009 [5], but
further studies rejected this hypothesis [6], and, as of today, the
causes of ME/CFS remain obscure. Drawing an analogy from the
evolution of the human brain, ME/CFS may even be regarded as a
‘‘phylogenic disease’’ [7–11], according to principle of ‘‘integrated
phylogeny’’ of the primate brain [12].
Exposure to heavy metals, with particular reference to dental
amalgams, has been considered among the triggers of ME/CFS,
and the attention has been focused mostly on mercury and gold
[13,14]. According to Stejskal et al. [13], heavy metals might be
responsible for inflammatory processes that may modulate the
hypothalamic-pituitary-adrenal axis and trigger the multiple,
non-specific, symptoms characterizing ME/CFS. These Authors no-
ticed in 1999 that in certain ME/CFS patients cadmium was a sen-
sitizer for blood lymphocytes, and this observation was confirmed
in 2006 by Valentine-Thon et al. [15] who described cadmium-sen-
sitization in metal-exposed individuals showing a number of
symptoms superimposable to those of ME/CFS. Nevertheless, the
precise role of cadmium in the aetiology or pathogenesis of ME/
CFS is not well understood, and the target organ of cadmium tox-
icity responsible for ME/CFS symptoms is not known. Probably,
also because of this lack of knowledge, ME/CFS is not considered
among the risk hazards associated with cadmium exposure. Here
we hypothesize that cadmium, one of the most important occupa-
tional and environmental heavy metal pollutants, might be associ-
ated with, or responsible for, some of the neurological findings
recently described in ME/CFS.The hypothesis
Cadmiummight cause brain alterations triggering or perpetuat-
ing the symptoms of ME/CFS. The hypothesis stems from the
observation that the effects of cadmium on neurons and blood ves-
sels are consistent with the pathologic alterations observed in ME/
CFS patients.Cadmium and neuronal cell death in ME/CFS
Since ME/CFS is considered a neurological disorder, several at-
tempts have been made to detect alterations in the brain of ME/
CFS patients. A recent study using a fully automated, observer-
independent procedure to study morphological alterations of the
central nervous system, demonstrated that ME/CFS patients had
an average decrease of the volume of the gray matter of about
8% compared to matched healthy controls [16]. The gray matter
volume reduction was significantly associated with objective
reduction of physical activity in ME/CFS patients [16]. Gray matter
volume reduction was not localized in any particular area of the
brain and it was not associated with a concomitant reduction in
white matter, thus indicating that the phenomenon was specific
to neurons. Gray matter volume reduction could then be held
accountable for most of the symptoms of ME/CFS. It is therefore
interesting to notice that it was recently demonstrated that cad-
mium induced neuronal death in cortical neurons through a com-
bined mechanism of apoptosis and necrosis involving reactive
oxygen species generation and lipid peroxidation [17]. It could
then be hypothesized that cadmium-induced neuronal cell death
might be responsible for some of the well known effects of cadmiumon the central nervous system, with particular reference to a de-
crease in attention level and memory in exposed humans [18] as
well as to a diminished ability for training and learning in rats ex-
posed to cadmium during their neonatal life [19]. It is worth men-
tioning, in the context of our hypothesis, that attention and
memory deficit are among the most debilitating symptoms in
ME/CFS patients [20,21]. Although the effects of cadmium on neu-
ronal cells in culture have been described in several papers [22], its
effects on human central nervous system neurons in vivo have not
yet been demonstrated. However, the recently described cad-
mium-induced apoptosis of the motor neurons of the ventral horns
in cultured explants from human foetal spinal cords (10–11 weeks
gestational age) [23], suggests that the effects observed in vitro
could actually occur also in vivo. This notwithstanding, the demon-
stration of a link between cadmium exposure and neuronal cell
death in living adult human brain is missing as well as still missing
is the demonstration of a link between cadmium exposure and ME/
CFS.
In order to test the hypothesis that cadmium exposure is asso-
ciated with ME/CFS, we propose to measure cadmium exposure in
a cohort of ME/CFS patients compared with matched healthy con-
trols. Cadmium exposure could be assessed by different methods;
determination of hair mineral contents by inductively coupled
plasma-mass spectrometry could be a simple and non-expensive
method [24]. This method allows quick determination of absolute
cadmium concentration as well as measurement of the ratios be-
tween physiological minerals and cadmium. For example, in a cer-
tified ME/CFS patient, we observed that hair cadmium content was
within the normal range, whereas the ratios calcium/cadmium,
magnesium/cadmium and sodium/cadmium, were well below
the normal ranges. This finding, although anecdotic and presented
here only to support the feasibility of testing our hypothesis, might
suggest that cadmium could substitute for those physiological
minerals at the cellular level.
The hypothesis that cadmium exposure is associated with neu-
ron reduction in vivo and with ME/CFS, could be tested by measur-
ing gray matter volume in un-exposed healthy controls, exposed
non-ME/CFS subjects, un-exposed ME/CFS patients and exposed
ME/CFS patients. This latter approach, however, would require an
imaging procedure that is simpler and less expensive than that de-
scribed in [16] which used high resolution structural magnetic res-
onance imaging. To this end, we developed a modified procedure
for transcranial sonography using a linear probe that is routinely
used for muscle-skeletal ultrasound imaging instead of the sector
array with a small footprint used for traditional transcranial sonog-
raphy. We observed that such a procedure allowed detailed visual-
ization of the cortex of the temporal lobe, a finding that is in itself
potentially important for the diagnosis and follow-up of ME/CFS
patients. Thus, it is well known that the temporal lobe is involved
in the processing of those functions, such as semantics and mem-
ory, that are often compromised in ME/CFS patients [25]. The
parameters adopted for visualization of the temporal cortex al-
lowed to distinguish the meninges, the subarachnoidal space and
the cortex (Fig. 1). The meninges appeared as a well organized ar-
ray of layers of about 4 mm thickness. The thickness of the cortex
measured in our study (3.9 mm) led us to hypothesize that we
were observing the temporal areas designated by von Economo
as TG and TE, i.e. those areas involved in the control of eye move-
ments and balance in standing position (area TE), social behaviour,
mood and decision making (area TG) [26]. It is worth remembering
that most of these functions are altered to various degree in ME/
CFS patients [2,4]. As a matter of fact, many of the neurocognitive
deficits used to define the syndrome (difficulty in processing
information, slowed thought, impaired concentration, disorienta-
tion, cognitive overload, difficulty with making decisions, slowed
speech, acquired or exertional dyslexia, short-term memory loss,
Fig. 1. Two dimension image of the temporal region obtained by transcranial sonography. We used an Esaote MyLabFive ultrasound imaging machine approved for many
applications including cephalic (brain) imaging. We used the default settings for adult transcranial imaging, but instead of a transcranial probe, we used a conventional linear
probe for muscle-skeletal examination and we selected 7.5 MHz frequency. Acoustic power was set to 1.0. The length of the probe was about 4 cm, i.e. much less than the size
of the temporal cortex that is 7–8 cm. The temporal squama appears as an hyper-reflecting (white) irregular line of about 1.5 mm thickness. The meninges appear as a well
organized array of layers of about 4 mm thickness. The sub-arachnoidal space (white arrow) is identified by two hyper-reflecting (white) lines sandwiching an hypo-reflecting
(black) space containing liquor. The size of the sub-arachnoidal space was about 0.6 mm. The neuronal layers of the temporal cortex (3.9 mm thickness) appear as alternate
layers of hyper- and hypo-reflecting structures. The thickness of the cortex corresponds to that of the TE and TG areas. Two areas with organized echo-structure
corresponding to neuronal layers VI (polymorphic cells) and V (deep pyramidal cells) could also be visualized.
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by the temporal lobe.
The spatial resolution and the ability to visualize structures of
200–300 lm size, led us to hypothesize that the linear structures
(alternate gray-white stripes) parallel to the sub-arachnoidal space
could be referred to the well known neuronal layers of the cortex
[27]. Detailed study of these layers in ME/CFS subjects exposed
or non-exposed to cadmium might prove instrumental in demon-
strating whether cadmium affects neuronal viability in vivo and/
or whether these changes are related with ME/CFS.Fig. 2. Pulsating arterial blood vessels in the meninges and inCadmium and angiogenesis in ME/CFS
We recently described the paradoxical effects of cadmiumon the
angiogenesis induced by cancer cells [28]. The effect was termed
‘‘paradoxical’’ because cadmium, a known carcinogen, exerted an
apparent anti-cancer effect by inhibiting cancer cell-stimulated
angiogenesis. The effects of cadmium on angiogenesis, however,
are complex and a dual effect has been recently described: it
appears that at low dose it stimulates angiogenesis, whereas at
higher doses it inhibits new blood vessel formation [29]. The rolethe temporal cortex just below the sub-arachnoidal space.
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Cerebral blood flow is decreased in most, but not all, ME/CFS pa-
tients [30], and the cortical blood flow appears to be most affected
[31]. The reduction of cerebral blood flow led theAuthors to hypoth-
esize that low global cerebral flow was associated with abnormal
brain neuroimaging results and objective evidence of brain dysfunc-
tion in the form of reduced cognitive testing scores [30]. Here we
hypothesize that cadmium exposure could be associated with re-
duced cerebral blood flow in exposed ME/CFS patients because of
the disruptive effects of cadmium on angiogenesis.
In order to test the hypothesis that cadmium exposure is asso-
ciated with reduction in cerebral blood flow in the cortex of ME/
CFS patients, we propose to measure cadmium exposure in a co-
hort of ME/CFS patients compared with matched healthy controls,
and then measure cerebral cortex blood flow in un-exposed
healthy controls, exposed non-ME/CFS subjects, un-exposed ME/
CFS patients and exposed ME/CFS patients. Cerebral cortex blood
flow could be measured with functional magnetic resonance imag-
ing as in [30] and/or also with the transcranial sonography tech-
nique described above. In fact, with the type of setting described
and using Doppler technique, we could also observe arterial vascu-
larisation of the meninges and of cortex of the temporal lobe and
pulsating arteries of about one mm diameter could be easily visu-
alized (Fig. 2). The use of transcranial sonography of the temporal
lobe could prove easier and certainly less expensive than func-
tional magnetic resonance imaging and thus become part of rou-
tine examination of ME/CFS patients. Since reduction of cerebral
blood flow in ME/CFS patients occurs across nearly every region as-
sessed by functional magnetic resonance imaging [30] or by xe-
non-computed tomography [31], the temporal lobe could
represent an easily accessible region of the human brain to be
studied by transcranial sonography.
Consequences of the hypothesis and discussion
If our hypothesis is demonstrated correct, the consequences
could affect prevention, early diagnosis, and treatment of ME/CFS.
In addition, if an association between cadmium exposure and ME/
CFS is demonstrated, in all or in specific subsets of ME/CFS patients,
this would have important repercussions in the definition of clinical
cases and in forensic and insurance-related matters. Thus, in those
patients, ME/CFS could be considered as consequence of occupa-
tional or accidental exposure to cadmium.
Implications in prevention are quite obvious even though there
already is general consensus in limiting the exposure to cadmium
because of its known carcinogenic effects. Nevertheless, demonstra-
tion of an association between cadmium exposure and ME/CFS
could lead to more stringent limits for exposure as well as to the
search for other symptoms in cadmium-exposed subjects in addi-
tion to those already established. Implications in early diagnosis
could entail the evaluation of symptoms typical of ME/CFS in cad-
mium-exposed subjects and also the search for signs of exposure
to cadmium in subjects diagnosed with ME/CFS. In addition, if the
neurological alterations previously described in ME/CFS patients
[16] could be easily and reproducibly assessed through the transcra-
nial sonography procedure described in this study, this simple and
non-expensive technique could be used in early diagnosis and fol-
low-up of the syndrome, whether associated with cadmium expo-
sure or not. Finally, if an association between cadmium exposure
andME/CFS is demonstrated, also themanagement of the syndrome
could be affected. Thus, nutritional supplementation of magnesium
and zinc have been proposed in the prophylaxis and therapy of cad-
mium exposure [32], and it is interesting to notice that an old ran-
domised controlled trial comparing a magnesium supplement
with placebo found beneficial effects of magnesium on ME/CFS pa-
tients’ symptom profiles [33].In conclusion, the hypothesis that cadmium is associated with,
or even responsible for many, if not all, the symptoms and the neu-
rological alterations typical of ME/CFS, is easily ‘‘falsifiable’’ accord-
ing to Popper’s criteria [34], and the critical tests that could prove
our hypothesis wrong can be easily performed.Conflict of interest statement
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